STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. To cope, we are relying, as always, on a cuppa stimulation.
- ▪Good morning, everyone, and welcome to another working week.
- ▪We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.
- ▪To cope, we are relying, as always, on a cuppa stimulation.
STAT News files mainly under health. We currently carry 213 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT |
| Canonical URL | https://www.statnews.com/pharmalot/2026/07/27/fda-panel-peptide-votes-amgen-fights-tavneos-withdrawal/?utm_campaign=rss |
| Publication time | Mon, 27 Jul 2026 13:19:47 +0000 |
| Retrieval time | 2026-07-27T13:38:34.222Z |
| Last seen | 2026-07-27T13:38:34.222Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | SMKbkoogZcTW · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more Argenx to pay $2.2 billion to buy Forte Biosciences to expand its immunology pipeline Manage alerts for this article Email this article Share this article Alex Hogan/STAT By Ed SilvermanJuly 27, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
